The new application of phenylephrine hydrochloride

A phenylephrine and pharmaceutical technology, applied in the field of medicine, can solve the problem of no phenylephrine hydrochloride and the like

Active Publication Date: 2022-05-17
SYNOGENBIOPHARMACO LTD NANJING CHINA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant report on the induction of endogenous cardiomyocyte proliferation by phenylephrine hydrochloride

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The new application of phenylephrine hydrochloride
  • The new application of phenylephrine hydrochloride
  • The new application of phenylephrine hydrochloride

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1, the in vitro test that phenylephrine hydrochloride (Phenylephrine Hcl) promotes rat cardiomyocyte proliferation

[0040] (1) Culture of Cardiomyocytes of SD Rats

[0041] Cardiomyocytes from SD rats born 3 days old were isolated and cultured in DMEM high glucose medium (Hyclone) + 5% horse serum (GIBCO) at 37 degrees in a 5% carbon dioxide incubator.

[0042] (2) Experimental grouping and processing

[0043] Isolate cardiomyocytes from SD rats, add 5% horse serum (GIBCO) + DMEM high-glucose medium (Hyclone), and add cytarabine (final concentration 20umol / L) to inhibit the growth of non-cardiomyocytes. Infect cTnT-mAG-hGeminin (1 / 110) virus (MOI value of virus infection=100) after 48 hours of adherence, after another 24 hours, replace with DMEM culture medium containing 0.5% FBS, add drugs in groups, and group as follows:

[0044] a. Experimental group: treated with phenylephrine hydrochloride (the final concentration in the medium is 2 μmol / L) for 24 hours...

Embodiment 2

[0050] Embodiment 2, the in vitro test that phenylephrine hydrochloride promotes neonatal rat cardiomyocytes to enter the cell cycle

[0051] Isolate the rat cardiomyocytes born 3 days old, add phenylephrine hydrochloride (final concentration in the culture medium is 2 μ mol / l), use DMEM+DMSO as the control (control), wash three times with PBS after 48 hours, 4% PFA ( Paraformaldehyde) fixed at room temperature for 15 min, washed three times with PBS, blocked at room temperature with 1% BSA / PBS / 0.1% Triton for 1 h, and added primary antibody after 1 h: Anti-α-Actinin (1:300, sigma, mouse, A7811), Phospho- Histone H3 (Ser10) antibody (1:300, CST, rabbit, 9701S), Anti-Ki67 (1:300, abcam, rabbit, ab15580) overnight at 4°C, washed 4 times with 1% BSA / PBS / 0.02% Tween, Add secondary antibodies: goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody (1:500, Invitrogen, A32731), goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody (1:500 , Life technologies...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine application of phenylephrine. The use is the application of phenylephrine or its pharmaceutically acceptable salts and esters in the preparation of drugs for promoting cardiomyocyte proliferation. The present invention proves through experiments that phenylephrine can promote the proliferation of rat cardiomyocytes. Therefore, phenylephrine can be used in related fields such as preparation of drugs for promoting myocardial cell proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a new drug application of phenylephrine hydrochloride. Background technique [0002] At present, cardiovascular disease has become the number one killer threatening human health. There are 40 million heart failure patients worldwide, and it has become the main cause of human death. Studies have found that cardiomyocytes in mammals gradually lose their ability to proliferate after adulthood. Once myocardial infarction occurs, the loss of cardiomyocytes will be irreversible. There are about 2-4 billion cardiomyocytes in an adult, about 25% of cardiomyocytes will be lost within a few hours after myocardial infarction, and the remaining cardiomyocytes have very limited proliferation ability, which is not enough to restore the contractile function of the heart, and the patient will eventually suffer from heart failure die. To solve this problem, in addition to surgery, basic tran...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/137A61P9/04A61P9/10C12N5/077
CPCA61K31/137A61P9/04A61P9/10C12N5/0657C12N2501/81
Inventor 卜晔杜建勇郑丽霞吴青朱小君熊敬维
Owner SYNOGENBIOPHARMACO LTD NANJING CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap